Aude de Gassart

Company: ImCheck Therapeutics

Job title: Head of Preclinical Model Development

Seminars:

Panel Discussion: How to Predict Your Immuno-Modulation & Immuno-Stimulatory Response? 3:25 pm

The potential of using IO, combinational or cell therapy to dial up another biologic to aid in the anti-tumour response. Could this be the next phase of development for immuno-oncology and what are the potential limitations of this approach? This panel will discuss: Methods of stimulating/dialling up a biologic Understanding of the differences between alternate…Read more

day: Day Two

Gamma Delta T-Cell Therapy: Development of ICT01, A First-In- Class, Anti-BTN3A Antibody For Activating Vγ9Vδ2 T Cell–Mediated Antitumor Immune Response 12:25 pm

Preclinical models for the development of monoclonal antibody targeting BTN3A, a membrane receptor with no ortholog in mice Biomarker package to support Phase 1 clinical studies with a first-in-class therapeutic activating Vg9Vd2 T cell–mediated antitumor immune response  How biomarkers allow to define the best combination strategiesRead more

day: Day Two